254 Recruiting Trials

Clinical Trials
in Montana

Browse 254 recruiting clinical trials currently enrolling participants in Montana. Search by condition to find trials you may qualify for, at no cost.

Showing 15 of 254 recruiting trials in Montana

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
N/A Athens, Alabama +4 sites · Lumbar Spinal Stenosis
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
PHASE3 Anchorage, Alaska +4 sites · Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
PHASE3 Anchorage, Alaska +4 sites · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
PHASE3 Birmingham, Alabama +4 sites · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Recruiting
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
PHASE2 Birmingham, Alabama +4 sites · Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recruiting
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
PHASE2 Anchorage, Alaska +4 sites · Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Recruiting
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
PHASE2 Phoenix, Arizona +4 sites · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
PHASE2 Birmingham, Alabama +4 sites · Acute Myeloid Leukemia, Myelodysplastic Syndrome
Recruiting
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
PHASE2 Dublin, California +4 sites · Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
PHASE3 Tucson, Arizona +4 sites · Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
PHASE2 Little Rock, Arkansas +4 sites · Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
PHASE3 Birmingham, Alabama +4 sites · Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
PHASE3 Bakersfield, California +4 sites · Non-small Cell Lung Cancer
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
PHASE3 Phoenix, Arizona +4 sites · Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Recruiting
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
PHASE2 Birmingham, Alabama +4 sites · Core Binding Factor Acute Myeloid Leukemia
Recruiting
See all 254 results in Montana

Check Your Eligibility

Create a free profile and our AI will match you to trials in Montana you may qualify for.

Get Matched — Free
No insurance required
Search by Condition in Montana
Diabetes Cancer Breast Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
Browse Other States
California Texas New York Florida Illinois Pennsylvania Ohio Georgia North Carolina Michigan New Jersey Washington Arizona Massachusetts Tennessee Colorado Minnesota Maryland Wisconsin Oregon